These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19912555)

  • 1. Predictive familial risk factors and pharmacological responses in ADHD with comorbid disruptive behavior disorders.
    Bandou N; Koike K; Matuura H
    Pediatr Int; 2010 Jun; 52(3):415-9. PubMed ID: 19912555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
    Masi G; Manfredi A; Nieri G; Muratori P; Pfanner C; Milone A
    J Clin Psychopharmacol; 2017 Oct; 37(5):590-594. PubMed ID: 28806385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
    Arnold LE; Gadow KD; Farmer CA; Findling RL; Bukstein O; Molina BS; Brown NV; Li X; Rundberg-Rivera EV; Bangalore S; Buchan-Page K; Hurt EA; Rice R; McNamara NK; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):203-12. PubMed ID: 25885010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
    Yılmaz S; Bilgiç A; Hergüner S
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):158-60. PubMed ID: 24168715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical trial.
    Jahangard L; Akbarian S; Haghighi M; Ahmadpanah M; Keshavarzi A; Bajoghli H; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
    Psychiatry Res; 2017 May; 251():182-191. PubMed ID: 28213188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder.
    Winters DE; Fukui S; Leibenluft E; Hulvershorn LA
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):298-305. PubMed ID: 29708762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders.
    Ter-Stepanian M; Grizenko N; Zappitelli M; Joober R
    Can J Psychiatry; 2010 May; 55(5):305-12. PubMed ID: 20482957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.
    Farmer CA; Brown NV; Gadow KD; Arnold LE; Kolko DG; Findling RL; Molina BS; Buchan-Page KA; Rice RR; Bangalore SS; Bukstein O; Rundberg-Rivera EV; McNamara N; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):213-24. PubMed ID: 25885011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comorbidity of disruptive behavioral disorders and attention-deficit hyperactivity disorder--indicator of severity in problematic behavior?
    Nordström T; Ebeling H; Hurtig T; Rodriguez A; Savolainen J; Moilanen I; Taanila A
    Nord J Psychiatry; 2013 Aug; 67(4):240-8. PubMed ID: 23126481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of methylphenidate treatment on suspiciousness in children with ADHD alone or comorbid with ODD.
    Golubchik P; Weizman A
    Int J Psychiatry Clin Pract; 2018 Jun; 22(2):109-114. PubMed ID: 28959903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder.
    Günther T; Herpertz-Dahlmann B; Jolles J; Konrad K
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):725-35. PubMed ID: 17201616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anxiety and disruptive behavior mediate pathways from attention-deficit/hyperactivity disorder to depression.
    Roy A; Oldehinkel AJ; Verhulst FC; Ormel J; Hartman CA
    J Clin Psychiatry; 2014 Feb; 75(2):e108-13. PubMed ID: 24602257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.
    Snyder R; Turgay A; Aman M; Binder C; Fisman S; Carroll A;
    J Am Acad Child Adolesc Psychiatry; 2002 Sep; 41(9):1026-36. PubMed ID: 12218423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent differences in attentional processes in ADHD and disruptive behavior disorder.
    Günther T; Jolles J; Herpertz-Dahlmann B; Konrad K
    Dev Neuropsychol; 2009; 34(4):422-34. PubMed ID: 20183708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder.
    Gau SS; Ni HC; Shang CY; Soong WT; Wu YY; Lin LY; Chiu YN
    Aust N Z J Psychiatry; 2010 Feb; 44(2):135-43. PubMed ID: 20113302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does oppositional defiant disorder have temperament and psychopathological profiles independent of attention deficit/hyperactivity disorder?
    Kim HW; Cho SC; Kim BN; Kim JW; Shin MS; Yeo JY
    Compr Psychiatry; 2010; 51(4):412-8. PubMed ID: 20579516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.